Market news

White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.H.C. Wainwright Conference Presentation...

Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

Submitted First Module of Modular PMA Application to FDASubsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business...

Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build.

Envoy Medical Inc. (NASDAQ:COCH) on Tuesday said it surpassed the three-month milestone for all 56 patients enrolled in the company’s pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant. Envoy Medical Completes Three-Month Milestone In Acclaim Trial The update marks another important clinical trial milestone as the company continues to build momentum with the hearing industry. Read Also: EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant

Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

Envoy Medical Inc. (NASDAQ:COCH) on Tuesday reported 12-month results from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant, with hearing performance continuing to improve over previously reported six-month data. The company said participants achieved a mean Consonant-Nucleus-Consonant (CNC) word recognition score of 53.2% at the 12-month mark, compared with a pre-implantation baseline of 15.2%. The 38.0 pe

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 monthsWhite Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants